Colorectal Oncogenomics Group

Discovering the causes of colorectal cancer, reducing its incidence, and improving patient outcomes.
Group Photo


Our research includes the identification and investigation of clinically and biologically relevant subtypes of colorectal cancer (CRC), including both familial and non-familial CRC, that can be identified through genetic, epigenetic, somatic and histopathological characterisation of CRC tumours and their pre-malignant lesions (polyps).

Key research areas
  • Identifying novel genetic risk factors for CRC.
  • Improving our understanding of major CRC-related diseases, such as Lynch Syndrome and Serrated Polyposis Syndrome
  • Identifying biomarkers of risk and poor prognosis in CRC.


Recent presentations

  • DNA mismatch repair deficient endometrial cancer, Merck Sharpe Dohme MSI-H Tumour Advisory Board, 5 October 2018.
  • Update on Serrated Polyposis, European Hereditary Tumour Group meeting, Nice, France, 25 September 2018.
  • NTHL1 heterozygous mutation carriers and risk of Colorectal Cancer, European Hereditary Tumour Group meeting, Nice, France, 24 September 2018.

Recent activities

  • 3 - 4 September, 2018: Attended and presented at Familial Aspects of Cancer: Research and Practice in Kingscliff, NSW.
  • December 2017 - February 2018: James Chan undertakes student project investigating copy number variation in Familial Colorectal Cancer Type X.
  • 7 January, 2018: Dr Harindra Jayasekara awarded Victorian Cancer Agency Early Career Seed Grant for his project Can genomic profiling help predict who will get a second bowel tumour?
  • 28 November, 2017: Invited speaker at the Eastern Gynaecological and Obstetrical Society, Annual Partners Dinner, in Melbourne.